Continuous activation of cell surface receptors increases signaling that can promote oncogenic transformation. One receptor, EphA2, has been identified as a driver of lung cancer, but its interacting partners are not well characterized.
https://news.vumc.org/2020/11/12/therapeutic-target-lung-cancer/#new_tab
![New therapeutic target for lung cancer](/sites/default/files/drupalfiles/vanderbilt_news/epha2-300x262_78.png)